Laurie Glimcher - Bristol-Myers Squibb Independent Director
Director
Dr. Laurie H. Glimcher, M.D. is no longer Independent Director of BristolMyers Squibb Company effective July 21, 2017. She was the President and Chief Executive Officer of Dana Farber Cancer Institute, Inc. since October 2016. She has also served as Principal Investigator and Director of the Dana FarberHarvard Cancer Center and as the Susan Smith Professor of Medicine at Harvard Medical School since December 2016. Dr. Glimcher served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs from January 2012 to September 2016. She was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School from 1990 to December 2011. Dr. Glimcher is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences and a Fellow of the Royal Society of Biology . She is the former President of the American Association of Immunologists and serves as a member of the American Asthma Foundation, Cancer Research Institute and Prix Galien Scientific Advisory Boards and the Lasker Award Jury. Dr. Glimcher is also a member of the American Association for Cancer Research, Association of American Cancer Institutes, and the American Society of Clinical Oncology. She is also a Director of the Parker Institute for Cancer Immunotherapy.
| Age | 64 |
| Professional Marks | Ph.D |
| Phone | 212-546-4000 |
| Web | http://www.bms.com |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Franz Humer | Chugai Pharmaceutical Co | 69 | |
| Keiko Yamagami | Astellas Pharma | 56 | |
| Judy Lewent | GlaxoSmithKline PLC ADR | 71 | |
| Yukio Kobayashi | Otsuka Holdings Co | 83 | |
| Makoto Takeuchi | Astellas Pharma | N/A | |
| Weiying Wang | AstraZeneca PLC ADR | N/A | |
| Hans Wijers | GlaxoSmithKline PLC ADR | 64 | |
| Akira Kamimura | Astellas Pharma | N/A | |
| Diane Souza | Sanofi ADR | 65 | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Emmanuel Babeau | Sanofi ADR | 51 | |
| Juichi Kawaguchi | Otsuka Holdings Co | 76 | |
| Bernard Poussot | Roche Holding Ltd | 66 | |
| Cornelia Bargmann | AstraZeneca PLC ADR | N/A | |
| Hitoshi Kanamori | Astellas Pharma | 63 | |
| Mamoru Togashi | Chugai Pharmaceutical Co | N/A | |
| Hiroko Sakai | Astellas Pharma | 56 | |
| Tsuguya Fukui | Daiichi Sankyo | 66 | |
| Laurent Attal | Sanofi ADR | 60 | |
| Tomokazu Fujisawa | Astellas Pharma | 59 | |
| Simon Moroney | Novartis AG ADR | 62 | |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
| Togo West, Independent Director | ||
| Karen Vousden, Director | ||
| Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Jose Baselga, Independent Director | ||
| Charles Bancroft, CFO, Executive Vice President | ||
| Gerald Storch, Independent Director | ||
| Louis Schmukler, President - Global Manufacturing and Supply | ||
| Michael Grobstein, Independent Director | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
| John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Karen Santiago, Senior Vice President Controller | ||
| Giovanni Caforio, COO, Director | ||
| Vicki Sato, Independent Director | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Laurie Glimcher, Independent Director | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Lamberto Andreotti, CEO, Director | ||
| Thomas Lynch, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Leung, General Counsel, Corporate Secretary | ||
| Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President Head - Business Development | ||
| Peter Arduini, Independent Director |
Bristol-Myers Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B |
Pair Trading with Bristol-Myers Squibb
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Dover could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dover when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dover - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dover to buy it.
The correlation of Dover is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dover moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dover moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dover can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |